TY - JOUR
T1 - Design of the SPIROMICS Study of Early COPD Progression
T2 - SOURCE Study
AU - SOURCE Investigators
AU - Curtis, Jeffrey L.
AU - Bateman, Lori A.
AU - Murray, Susan
AU - Couper, David J.
AU - Labaki, Wassim W.
AU - Freeman, Christine M.
AU - Arnold, Kelly B.
AU - Christenson, Stephanie A.
AU - Alexis, Neil E.
AU - Kesimer, Mehmet
AU - Boucher, Richard C.
AU - Kaner, Robert J.
AU - Barjaktarevic, Igor
AU - Cooper, Christopher B.
AU - Hoffman, Eric A.
AU - Barr, R. Graham
AU - Bleecker, Eugene R.
AU - Bowler, Russell P.
AU - Comellas, Alejandro
AU - Dransfield, Mark T.
AU - Freedman, Michael B.
AU - Hansel, Nadia N.
AU - Krishnan, Jerry A.
AU - Marchetti, Nathaniel
AU - Meyers, Deborah A.
AU - Ohar, Jill
AU - O'Neal, Wanda K.
AU - Ortega, Victor E.
AU - Paine, Robert
AU - Peters, Stephen P.
AU - Smith, Benjamin M.
AU - Wedzicha, Jadwiga A.
AU - Wells, J. Michael
AU - Woodruff, Prescott G.
AU - Han, Meilan K.
AU - Martinez, Fernando J.
AU - Huang, Yvonne J.
AU - Postow, Lisa
AU - Viviano, Lisa
N1 - Publisher Copyright:
© JCOPDF 2024.
PY - 2024/9
Y1 - 2024/9
N2 - Background: The biological mechanisms leading some tobacco-exposed individuals to develop early-stage chronic obstructive pulmonary disease (COPD) are poorly understood. This knowledge gap hampers development of disease-modifying agents for this prevalent condition. Objective: Accordingly, with National Heart, Lung and Blood Institute support, we initiated the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study of Early COPD Progression (SOURCE), a multicenter observational cohort study of younger individuals with a history of cigarette smoking and thus at-risk for, or with, early-stage COPD. Our overall objectives are to identify those who will develop COPD earlier in life, characterize them thoroughly, and by contrasting them to those not developing COPD, define mechanisms of disease progression. Methods/Discussion: SOURCE utilizes the established SPIROMICS clinical network. Its goal is to enroll n=649 participants, ages 30-55 years, all races/ethnicities, with ≥10 pack-years cigarette smoking, in either Global initiative for chronic Obstructive Lung Disease (GOLD) groups 0-2 or with preserved ratio-impaired spirometry; and an additional n=40 never-smoker controls. Participants undergo baseline and 3-year follow-up visits, each including high-resolution computed tomography, respiratory oscillometry and spirometry (pre- and postbronchodilator administration), exhaled breath condensate (baseline only), and extensive biospecimen collection, including sputum induction. Symptoms, interim health care utilization, and exacerbations are captured every 6 months via follow-up phone calls. An embedded bronchoscopy substudy involving n=100 participants (including all never-smokers) will allow collection of lower airway samples for genetic, epigenetic, genomic, immunological, microbiome, mucin analyses, and basal cell culture. Conclusion: SOURCE should provide novel insights into the natural history of lung disease in younger individuals with a smoking history, and its biological basis.
AB - Background: The biological mechanisms leading some tobacco-exposed individuals to develop early-stage chronic obstructive pulmonary disease (COPD) are poorly understood. This knowledge gap hampers development of disease-modifying agents for this prevalent condition. Objective: Accordingly, with National Heart, Lung and Blood Institute support, we initiated the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study of Early COPD Progression (SOURCE), a multicenter observational cohort study of younger individuals with a history of cigarette smoking and thus at-risk for, or with, early-stage COPD. Our overall objectives are to identify those who will develop COPD earlier in life, characterize them thoroughly, and by contrasting them to those not developing COPD, define mechanisms of disease progression. Methods/Discussion: SOURCE utilizes the established SPIROMICS clinical network. Its goal is to enroll n=649 participants, ages 30-55 years, all races/ethnicities, with ≥10 pack-years cigarette smoking, in either Global initiative for chronic Obstructive Lung Disease (GOLD) groups 0-2 or with preserved ratio-impaired spirometry; and an additional n=40 never-smoker controls. Participants undergo baseline and 3-year follow-up visits, each including high-resolution computed tomography, respiratory oscillometry and spirometry (pre- and postbronchodilator administration), exhaled breath condensate (baseline only), and extensive biospecimen collection, including sputum induction. Symptoms, interim health care utilization, and exacerbations are captured every 6 months via follow-up phone calls. An embedded bronchoscopy substudy involving n=100 participants (including all never-smokers) will allow collection of lower airway samples for genetic, epigenetic, genomic, immunological, microbiome, mucin analyses, and basal cell culture. Conclusion: SOURCE should provide novel insights into the natural history of lung disease in younger individuals with a smoking history, and its biological basis.
KW - SPIROMICS
KW - health-related quality of life
KW - imaging phenotypes
KW - preserved ratioimpaired spirometry
KW - smoking-related lung disease
UR - http://www.scopus.com/inward/record.url?scp=85206111581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85206111581&partnerID=8YFLogxK
U2 - 10.15326/jcopdf.2023.0490
DO - 10.15326/jcopdf.2023.0490
M3 - Article
AN - SCOPUS:85206111581
SN - 2372-952X
VL - 11
SP - 444
EP - 459
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
IS - 5
ER -